ECSP993020A - COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY - Google Patents

COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY

Info

Publication number
ECSP993020A
ECSP993020A ECSP993020A ECSP993020A EC SP993020 A ECSP993020 A EC SP993020A EC SP993020 A ECSP993020 A EC SP993020A EC SP993020 A ECSP993020 A EC SP993020A
Authority
EC
Ecuador
Prior art keywords
compositions
fragility
combination therapy
oxo
phenyl
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Hua Zhu Ke
David Duane Thompson
Lydia Codetta Pan
Mei Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP993020 priority Critical patent/ECSP993020A/en
Publication of ECSP993020A publication Critical patent/ECSP993020A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a composiciones de combinación farmacéuticas y a procedimientos que contienen (-)-cis-6-fenil-5-(4-(2-pirrolidin-1-il-etoxil)-fenil)-5,6,7,8-tetrahidronaftalen-2-ol o una de sus sales farmacéuticamente aceptables y 2-aminoN-(2-(3a R-bencil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pirazolo [4,3-c] piridin-5-il) -1R-benciloximetil-2-oxo-etil)-isobutiramida o una de sus sales farmacéuticamente aceptables, a procedimientos para usar tales composiciones y a estuches que contienen tales composiciones. Las composiciones son de utilidad para tratar fragilidad musculoesquelética, incluyendo osteoporosis, fractura osteoporótica, masa osea reducida, fragilidad y masa muscular reducida.This invention relates to pharmaceutical combination compositions and processes containing (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7,8 -tetrahydronaphthalen-2-ol or one of its pharmaceutically acceptable salts and 2-aminoN- (2- (3a R-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo [4,3-c] pyridin-5-yl) -1R-benzyloxymethyl-2-oxo-ethyl) -isobutyramide or one of its pharmaceutically acceptable salts, to procedures for using such compositions and to kits containing such compositions. The compositions are useful for treating musculoskeletal fragility, including osteoporosis, osteoporotic fracture, reduced bone mass, fragility, and reduced muscle mass.

ECSP993020 1999-06-16 1999-06-16 COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY ECSP993020A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993020 ECSP993020A (en) 1999-06-16 1999-06-16 COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993020 ECSP993020A (en) 1999-06-16 1999-06-16 COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY

Publications (1)

Publication Number Publication Date
ECSP993020A true ECSP993020A (en) 1999-08-12

Family

ID=42044009

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993020 ECSP993020A (en) 1999-06-16 1999-06-16 COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY

Country Status (1)

Country Link
EC (1) ECSP993020A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723902B2 (en) 2014-09-04 2023-08-15 Helsinn Healthcare Sa Medical treatments based on anamorelin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723902B2 (en) 2014-09-04 2023-08-15 Helsinn Healthcare Sa Medical treatments based on anamorelin

Similar Documents

Publication Publication Date Title
HK1050899A1 (en) Pteridine compounds for the treatment of psoriasis
DE60037836D1 (en) ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis
LU91710I2 (en) Pazopanib, optionally in the form of a pharmaceutically acceptable salt or solvate thereof
BR9714155A (en) Prevention of bone mass loss and replacement by certain prostaglandin agonists.
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
BR0105457A (en) Therapeutic combinations to stimulate bone growth
SE0101322D0 (en) Novel compounds
PA8475901A1 (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
CO5070584A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES (-) - CIS-6-PHENYL-5- (4- (2-PIRROLIDIN-1-IL-ETOXI) -PENYL) -5,6,7,8-TETRAHYDRONAFTALEN -2-OL AND PARTIROID HORMONE
UY25557A1 (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
ECSP993020A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
MXPA02001204A (en) Calcilytic compounds.
IL158186A0 (en) Pharmaceutically active compounds and methods of use
MEP5608A (en) Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridyl- methylaminomethyl]- chromane and its physiologically acceptable salts
PT1406859E (en) Substituted 4-aminocyclohexanol derivatives
ECSP993021A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
GB0112494D0 (en) New therapeutic use
DE69916932D1 (en) Combination therapeutic agents containing a selective estrogen receptor modulator and prostaglandin E2
AU2003270164A1 (en) Kit for the therapy of capital and subcapital humerus fractures and humerus head prostheses
ECSP993016A (en) THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR
AU2002361254A8 (en) Tracking early indicia of beauty treatment progress
AU2002339076A1 (en) Alkane diol derivatives as therapeutic agents for the treatment of bone conditions